FDA clears Envoy Medical (NASDAQ: COCH) to expand Acclaim cochlear implant pivotal trial

Rhea-AI Filing Summary

Envoy Medical, Inc. filed a current report describing a regulatory milestone for its fully implanted Acclaim® cochlear implant. The company announced that the U.S. Food and Drug Administration approved the expansion of its pivotal clinical trial for Acclaim to the final stage. This means the study can now move into its concluding phase under FDA authorization, an important step in the product’s clinical development.

Positive

• FDA approval to expand pivotal trial: The U.S. Food and Drug Administration approved Envoy Medical’s expansion of the pivotal clinical trial for its fully implanted Acclaim® cochlear implant to the final stage, marking a significant regulatory and development milestone.

Negative

• None.

Insights

Medical devices & regulatory strategy analyst

FDA cleared Envoy Medical’s Acclaim implant trial to its final pivotal stage.

Envoy Medical reports that the U.S. Food and Drug Administration has approved expansion of the pivotal clinical trial for its fully implanted Acclaim® cochlear implant to the final stage. Pivotal trials are typically the main studies used to support marketing applications, so progressing to a final stage is a key development step.

This update indicates regulators are allowing the company to continue advancing the Acclaim study design as proposed, which may reflect prior safety and performance data being sufficient for the next phase. However, the disclosure does not include clinical outcomes, timelines, or approval prospects, so it mainly confirms regulatory progress rather than final success.

For investors, the key point is that Acclaim remains in pivotal testing with FDA-approved expansion to a final stage as of October 7, 2025. Future press releases and SEC filings will be needed to understand enrollment progress, results, and any subsequent regulatory submissions based on this trial.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001840877 0001840877 2025-10-07 2025-10-07 0001840877 COCH:ClassCommonStockParValue0.0001PerShareMember 2025-10-07 2025-10-07 0001840877 COCH:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfClassCommonStockAtExercisePriceOf11.50PerShareMember 2025-10-07 2025-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 7, 2025

ENVOY MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40133		86-1369123
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

4875 White Bear Parkway White Bear Lake, MN		55110
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 900-3277

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share		COCH		The Nasdaq Stock Market LLC
Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share		COCHW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events

On October 7, 2025, Envoy Medical, Inc. (the “Company”) issued a press release announcing the U.S. Food and Drug Administration’s approval of the Company’s expansion of its pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage.

A copy of the press release is attached hereto and incorporated by reference herein as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Envoy Medical, Inc. Press Release, dated October 7, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENVOY MEDICAL, INC.
October 7, 2025	By:	/s/ Brent T. Lucas
		Brent T. Lucas
		Chief Executive Officer

2

FAQ

What did Envoy Medical (COCH) announce in this 8-K filing?

Envoy Medical reported that it issued a press release announcing the U.S. Food and Drug Administration’s approval of the expansion of its pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage.

What is the key regulatory development for Envoy Medicals Acclaim cochlear implant?

The key development is that the U.S. Food and Drug Administration approved the company’s expansion of its pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage.

When did Envoy Medical receive FDA approval to expand the Acclaim pivotal trial?

Envoy Medical stated that on October 7, 2025, it issued a press release announcing the U.S. Food and Drug Administration’s approval of the expansion of its pivotal clinical trial for the fully implanted Acclaim® cochlear implant to the final stage.

Which product is involved in Envoy Medicals newly expanded pivotal trial?

The product is Envoy Medical’s fully implanted Acclaim® cochlear implant, for which the pivotal clinical trial has been approved for expansion to the final stage.

Does this 8-K include the full press release from Envoy Medical?

The 8-K states that a copy of the press release announcing the FDA approval is attached as Exhibit 99.1 and incorporated by reference.

What exhibits are included with Envoy Medicals 8-K filing?

The filing lists Exhibit 99.1, the Envoy Medical, Inc. press release dated October 7, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.